Joseph Papa

Valeant's $930 Million iNova Pharma Sale Boosts Stock Price

Perrigo's Weak Near-Term Outlook Is Concerning

Valeant's Salix Story: To Sell Or Not To Sell?

Perrigo's Weak Near-Term Outlook Is Concerning

Valeant's Salix Story: To Sell Or Not To Sell?

Shares Pull Back As Problems Pile Up At Perrigo

Andrew Left On Valeant: 'Eliminating Price Gouging' Is Sole Agreement Between Presidential Nominees

Shares Pull Back As Problems Pile Up At Perrigo

Andrew Left On Valeant: 'Eliminating Price Gouging' Is Sole Agreement Between Presidential Nominees

The FDA Showing Valeant Some Love With Recent Drug Approvals

Ackman: Valeant Doesn't Have To Sell Core Assets